We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » EU Approves AstraZeneca’s Lynparza for Ovarian Cancer
EU Approves AstraZeneca’s Lynparza for Ovarian Cancer
AstraZeneca’s first-in-class ovarian cancer drug Lynparza will soon be available in Europe, following European Medicines Agency approval late this week.